Immunocore Holdings Ltd (IMCR) - Total Liabilities
Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) has total liabilities worth $705.94 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Immunocore Holdings Ltd to see how much of total assets are deployed in long-term investments.
Immunocore Holdings Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how Immunocore Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Immunocore Holdings Ltd's balance sheet.
Immunocore Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Immunocore Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Opple Lighting Co Ltd
SHG:603515
|
China | CN¥2.41 Billion |
|
Photronics Inc
NASDAQ:PLAB
|
USA | $237.37 Million |
|
Grand City Properties SA
F:GYC
|
Germany | €5.71 Billion |
|
Bestway Marine & Energy Technology Co Ltd
SHE:300008
|
China | CN¥3.30 Billion |
|
SFL Corporation Ltd
NYSE:SFL
|
USA | $2.59 Billion |
|
Supreme Petrochem Limited
NSE:SPLPETRO
|
India | Rs11.12 Billion |
|
PG Electroplast Limited
NSE:PGEL
|
India | Rs28.98 Billion |
|
Tecnoglass Inc
NYSE:TGLS
|
USA | $640.07 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Immunocore Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Immunocore Holdings Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunocore Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunocore Holdings Ltd (2018–2024)
The table below shows the annual total liabilities of Immunocore Holdings Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $648.79 Million | +184.36% |
| 2023-12-31 | $228.16 Million | +21.45% |
| 2022-12-31 | $187.86 Million | +6.89% |
| 2021-12-31 | $175.76 Million | +23.91% |
| 2020-12-31 | $141.85 Million | -37.34% |
| 2019-12-31 | $226.37 Million | +62.63% |
| 2018-12-31 | $139.19 Million | -- |
About Immunocore Holdings Ltd
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more